Navigation Links
Aratana Therapeutics Appoints Craig Tooman to Board of Directors
Date:5/9/2012

KANSAS CITY, Kan. and NEW YORK, May 9, 2012 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, has announced the appointment of Craig Tooman, to its Board of Directors.

During his distinguished career, Mr. Tooman has held various senior positions in the pharmaceutical industry in international finance, sales, market research, business intelligence, strategic business management, and investor relations. After nearly a decade with Pharmacia & Upjohn (now Pfizer), Mr. Tooman moved to the biotechnology industry.

Mr. Tooman has made substantial contributions to companies including Ilex Oncology, which was sold to Genzyme Corporation for $1.1 billion; Enzon Pharmaceuticals and Ikaria.  Mr. Tooman has recently been appointed CEO of Avanzar Medical, and he has been named entrepreneur-in-residence by the Cancer Prevention and Research Institute of Texas.

"Craig's exceptional track record guiding the evolution of different types of life sciences companies, his experience not just with finance but with all the disciplines that create a company's growth potential, and his ability to communicate with the financial community are skills Aratana will draw on extensively as we continue to develop new medicines to address unmet needs in companion animal health," says Board of Directors Chair Dr. Steven St. Peter.

Mr. Tooman has a Bachelor of Arts degree in economics with a minor in Japanese Language and a concentration in International Finance from Kalamazoo College. He received his MBA in Finance from the University of Chicago.

"Aratana's business model is unique and compelling in the animal health industry, and I believe the team guiding the company is exceptional," Mr. Tooman says. "I look forward to serving on the Board of Directors and helping shape the future of this very exciting enterprise."

About Aratana Therapeutics

Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.

Contact: Dr. Linda Rhodes, CEO (lrhodes@aratanarx.com), 732-895-5420


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces $20 Million Financing
2. Aratana Therapeutics Completes $15 Million Series B Financing
3. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
7. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, ... leading commercial provider of clinically actionable liquid biopsy ... announces that clinical data featuring its Target Selector™ ... tissue biopsy for the detection of actionable biomarkers ... from research sponsored by Sara Cannon Research Institute ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. ... a Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based ... “The System Integrator Partner certification gives customers confidence that our engineers are fully ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):